Revive Therapeutics Expands Research Partnership for Novel Formulation Development and Clinical Research of Psilocybin with the University of Wisconsin-Madison
Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19